Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Cancer Treat Rev. 2015 Jun 6;41(9):777–783. doi: 10.1016/j.ctrv.2015.06.001

Figure 1.

Figure 1

Mechanism of action of TAS-102: comparison with 5-FU-based fluoropyrimidines. Figure adapted from Wilson PM et al. Nat Rev Clin Oncol. 2014;11(5):282-298. Permission pending.

5′dFCR: 5′-deoxy-5-fluorocytidine; 5′dFUR: 5′-deoxy-5-fluorouridine; 5-FU: 5-fluorouracil; CDHP: 5-chloro-2,4-dihydroxypyridine; DPD: dihydropyrimidine dehydrogenase; dTTP: thymidine triphosphate; F3dTMP: trifluoromethyl deoxyuridine 5′-monophosphate; F3dTTP: trifluoromethyl deoxyuridine 5′-triphosphate; FdUDP: fluorodeoxyuridine diphosphate; FdUMP: fluorodeoxyuridine monophosphate; FdUTP: fluorodeoxyuridine triphosphate; dUTPase: deoxyuridine pyrophosphatase; FTD: α,α,α-trifluorothymidine (trifluridine); FUDP: fluorouridine diphosphate; FUMP: fluorouridine monophosphate; FUR: fluorouridine; FUTP: fluorouridine phosphate; NDK: nucleoside diphosphate kinase; OPRT: orotate phosphoribosyltransferase; TK: thymidine kinase; TP: thymidine phosphorylase; TPI: tipiracil hydrochloride; TS: thymidylate synthase; UMP-CMPK: uridine monophosphate-cytidine monophosphate kinase; UP: uridine phosphorylase.